

Herbst, Roy**Institution/Organization**

Yale Cancer Center

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

RSH

Disclosure of Potential Conflicts

RSH

COI Disclosure**Disclosures**

AstraZeneca: Pharmaceuticals Consulting, Personal

EMD Serono Inc.: Consulting, Personal

Immunocore: Consulting, Personal

Johnson and Johnson: Consulting, Personal

Merck & Company, Inc: Consulting, Personal

Mirati Therapeutics: Consulting, Personal

Novartis Oncology: Consulting, Personal

STCube Pharmaceuticals, Inc: Consulting, Personal

Xencor, Inc: Consulting, Personal

AstraZeneca: Pharmaceuticals Research (Clinical Trials), Institutional

Genentech/Roche: Research (Clinical Trials), Institutional

Merck & Company, Inc: Research (Clinical Trials), Institutional

Immunocore Holdings Limited: Board Member (non-executive/independent), Personal

to include stock options in 2021

Junshi Biosciences Co., Ltd.: Board Member (non-executive/independent), Personal

Cybrexa Therapeutics: Consulting, Personal

eFFECTOR Therapeutics, Inc.: Consulting, Personal

Eli Lilly and Company: Consulting, Personal

I-Mab Biopharma: Consulting, Personal

Next Cure: Consulting, Personal

Bolt Biotherapeutics: Consultant, Personal, 2500 options (intrinsic value as of 4/21/2021: \$0.00)

COI Disclosure Certification

RSH

Confidentiality Agreement

RSH

Standards of Conduct Agreement

RSH

IASLC's Tax-Exempt Status

RSH

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Those institutional amounts are the research study support.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?